/PRNewswire/ Cambrian BioPharma, a multi-asset longevity biotech, today announced that its CEO, James Peyer, has been selected as "BioTech Company CEO of.
- Fundraising led by Cambrian BioPharma and Solve FSHD Company expands pipeline with new program, VTA-120, for the treatment of facioscapulohumeral muscular dystrophy (FSHD) -BALTIMORE (BUSINESS WIRE) Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop novel cellular therap.